Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
May 16, 2022 08:00 ET
|
Affimed N.V.
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with...
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
May 12, 2022 10:31 ET
|
Affimed N.V.
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological...
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
May 06, 2022 16:02 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
CORRECTING and REPLACING -- Affimed N.V.
April 27, 2022 17:21 ET
|
Affimed N.V.
In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American...
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)
April 27, 2022 16:05 ET
|
Affimed N.V.
A presentation on the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13, in patients with CD30-positive lymphomas will be given in an...
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 18, 2022 11:28 ET
|
Affimed N.V.
HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their...
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
April 12, 2022 22:02 ET
|
Affimed N.V.
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Proposed Public Offering of Common Shares
April 12, 2022 16:03 ET
|
Affimed N.V.
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
April 10, 2022 12:05 ET
|
Affimed N.V.
100% objective response rate and improvement in the rate of complete responses (CR) from 38% to 62% after a second cycle in 13 patients treated at the recommended phase 2 dose (RP2D)Patients enrolled...
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors
April 08, 2022 13:23 ET
|
Affimed N.V.
The recommended phase 2 dose was determined at 480 mgAFM24 has demonstrated a well-managed safety profilePharmacodynamic activity was observed at doses of 160 mg and higherThe maximum tolerated dose...